Literature DB >> 17685412

Mechanisms of DNA breaks induction in vivo by 5-azacytidine: paths of micronucleus induction by azaC.

P Morales-Ramírez1, T Vallarino-Kelly, V L Cruz-Vallejo.   

Abstract

The aim of the present study was to correlate the time-response curves of micronucleated polychromatic erythrocyte (MN-PCE) induction by 5-azacytidine (azaC) with the possible processes involved in DNA break production; this is based on the results previously published by other authors. The MN-PCE induction at two different doses of azaC was determined by sampling blood from the tails of mice before the acute treatment and over nine periods of 8 h each afterwards. Both doses caused two peaks of MN-PCE induction, one at 32 h and another at 48 h, approximately; a shoulder was detected that remained high from 56 h up to the end of the study (72 h). These results suggest that azaC induced DNA breaks and subsequently MN (micronucleus) by three different mechanisms, and in agreement with data in the literature, these could be successively the following: (i) during excision of the large adduct comprising the DNA methyl transferase covalently linked to DNA; (ii) failure of recombination repair or mismatch repair; and (iii) persistent chromosome fragility in G-C rich sites due to DNA demethylation and chromatin decondensation.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 17685412     DOI: 10.1002/jat.1274

Source DB:  PubMed          Journal:  J Appl Toxicol        ISSN: 0260-437X            Impact factor:   3.446


  2 in total

1.  Downregulation of HO-1 promoted apoptosis induced by decitabine via increasing p15INK4B promoter demethylation in myelodysplastic syndrome.

Authors:  D Ma; Q Fang; P Wang; R Gao; J Sun; Y Li; X Y Hu; J S Wang
Journal:  Gene Ther       Date:  2015-02-05       Impact factor: 5.250

2.  Targeting the epigenome: effects of epigenetic treatment strategies on genomic stability in healthy human cells.

Authors:  Jan C Purrucker; Ulrich Mahlknecht
Journal:  Clin Epigenetics       Date:  2010-07-27       Impact factor: 6.551

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.